<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF9D180E-7AAF-479F-8D6A-91239520D6C2"><gtr:id>FF9D180E-7AAF-479F-8D6A-91239520D6C2</gtr:id><gtr:name>Zoology Ecology and Plant Science</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0AEFDD04-383A-4977-9F05-440376448760"><gtr:id>0AEFDD04-383A-4977-9F05-440376448760</gtr:id><gtr:name>International Centre for Genetic Engineering and Biotechnology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DB0666A7-AF7B-4D83-8327-4BDA6FB41C0B"><gtr:id>DB0666A7-AF7B-4D83-8327-4BDA6FB41C0B</gtr:id><gtr:name>Government of the United States of America</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F6B629B3-C879-405F-A7CD-88B6716CCAB2"><gtr:id>F6B629B3-C879-405F-A7CD-88B6716CCAB2</gtr:id><gtr:name>Burnet Institute</gtr:name><gtr:address><gtr:line1>GPO Box 2284</gtr:line1><gtr:postCode>3001</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/44BCECCF-49CB-46D7-BAA3-5B18144B0916"><gtr:id>44BCECCF-49CB-46D7-BAA3-5B18144B0916</gtr:id><gtr:name>Malaria GIA Reference Center - PATH MVI</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/322DDD33-7767-499D-B26C-E8DC0E14EC16"><gtr:id>322DDD33-7767-499D-B26C-E8DC0E14EC16</gtr:id><gtr:name>ExpreS2ion Biotechnologies</gtr:name><gtr:address><gtr:line1>Agern All? 1</gtr:line1><gtr:postCode>DK-2970</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/24A1EE66-AE01-4E27-9C73-48C3A1C90C77"><gtr:id>24A1EE66-AE01-4E27-9C73-48C3A1C90C77</gtr:id><gtr:name>PATH</gtr:name><gtr:address><gtr:line1>PATH</gtr:line1><gtr:line2>2201 Westlake Avenue, Suite 200</gtr:line2><gtr:line3>PO Box 900922</gtr:line3><gtr:postCode>98109</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DEAE3701-4328-4504-92F6-71375099B7DB"><gtr:id>DEAE3701-4328-4504-92F6-71375099B7DB</gtr:id><gtr:name>Naval Medical Research Center Unit-6</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Medical Sciences Division</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF9D180E-7AAF-479F-8D6A-91239520D6C2"><gtr:id>FF9D180E-7AAF-479F-8D6A-91239520D6C2</gtr:id><gtr:name>Zoology Ecology and Plant Science</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0AEFDD04-383A-4977-9F05-440376448760"><gtr:id>0AEFDD04-383A-4977-9F05-440376448760</gtr:id><gtr:name>International Centre for Genetic Engineering and Biotechnology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DB0666A7-AF7B-4D83-8327-4BDA6FB41C0B"><gtr:id>DB0666A7-AF7B-4D83-8327-4BDA6FB41C0B</gtr:id><gtr:name>Government of the United States of America</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F6B629B3-C879-405F-A7CD-88B6716CCAB2"><gtr:id>F6B629B3-C879-405F-A7CD-88B6716CCAB2</gtr:id><gtr:name>Burnet Institute</gtr:name><gtr:address><gtr:line1>GPO Box 2284</gtr:line1><gtr:postCode>3001</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44BCECCF-49CB-46D7-BAA3-5B18144B0916"><gtr:id>44BCECCF-49CB-46D7-BAA3-5B18144B0916</gtr:id><gtr:name>Malaria GIA Reference Center - PATH MVI</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/322DDD33-7767-499D-B26C-E8DC0E14EC16"><gtr:id>322DDD33-7767-499D-B26C-E8DC0E14EC16</gtr:id><gtr:name>ExpreS2ion Biotechnologies</gtr:name><gtr:address><gtr:line1>Agern All? 1</gtr:line1><gtr:postCode>DK-2970</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/24A1EE66-AE01-4E27-9C73-48C3A1C90C77"><gtr:id>24A1EE66-AE01-4E27-9C73-48C3A1C90C77</gtr:id><gtr:name>PATH</gtr:name><gtr:address><gtr:line1>PATH</gtr:line1><gtr:line2>2201 Westlake Avenue, Suite 200</gtr:line2><gtr:line3>PO Box 900922</gtr:line3><gtr:postCode>98109</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DEAE3701-4328-4504-92F6-71375099B7DB"><gtr:id>DEAE3701-4328-4504-92F6-71375099B7DB</gtr:id><gtr:name>Naval Medical Research Center Unit-6</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/72056FF9-D3CE-4186-BD73-491ABDB4EA85"><gtr:id>72056FF9-D3CE-4186-BD73-491ABDB4EA85</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Draper</gtr:surname><gtr:orcidId>0000-0002-9415-1357</gtr:orcidId><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000527"><gtr:id>011A9C36-D920-4140-AFCA-31690923C5F6</gtr:id><gtr:title>Clinical and Immunological Evaluation of T cell- and Antibody-Inducing Viral Vector Vaccines against Blood-Stage Malar</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000527</gtr:grantReference><gtr:abstractText>Malaria remains a huge public health problem in the developing world. The development of an effective vaccine remains an important but elusive goal. Malaria is caused by a parasite that first infects the liver before moving into the blood where it causes disease. A few vaccines have been developed recently that can kill some parasites in the liver, however, there is still no vaccine that can kill parasites in the blood.

This research will test a new vaccine technology against the parasites in the blood. These vaccines, developed by scientists at the Jenner Institute, Oxford University, use viruses that are genetically engineered to look like malaria parasites. The work will test the safety and effectiveness of these vaccines in volunteers in clinical trials in Oxford, and importantly also study the immune responses produced by them. Scientists can then attempt to figure out which immune responses are killing the parasites. This research will also assess how malaria infection can interfere with immune responses in humans in both the UK and Africa. It is extremely important to understand these interactions between malaria parasites and the human immune system, because we can use this information to help design better vaccines in the future.</gtr:abstractText><gtr:technicalSummary>The development of a highly effective malaria vaccine remains an important but elusive goal. To date, blood-stage malaria candidate vaccines, based primarily on protein-in-adjuvant formulations, have almost all been selected for clinical trials based on their ability to induce growth inhibitory antibodies - assessed using an in vitro assay that lacks T cells or monocytes. Despite these extensive efforts, these technologies have sadly shown limited or no success in clinical settings. A key contributing factor to these difficulties is our limited understanding of protective immune responses in vivo in humans against blood-stage parasites. However, there is growing evidence for the role of T cells and antibody Fc-mediated effector functions in immunity to blood-stage malaria and yet, to date, no vaccine has sought to induce such responses. This research seeks to address the merits of using viral vectored vaccines encoding blood-stage malaria antigens in humans in Phase I/IIa clinical trials. These vaccines induce strong and protective T cell and Th1-type antibody responses against encoded antigens in animal models, and now provide the first opportunity to address fundamental questions in humans regarding the contribution of cellular and antibody Fc-mediated immune responses to protective efficacy against blood-stage malaria. 



This research will aim to assess the safety, immunogenicity and efficacy of viral vector blood-stage malaria vaccines; develop a new in vivo assay of antibody Fc effector function; and address fundamental questions about the immuno-modulatory effects of blood-stage parasite exposure on cellular immune responses in both malaria-na?ve and naturally-exposed individuals. 



Summary of key goals:



1. Characterise the immunogenicity of viral vector blood-stage malaria vaccines in human volunteers using multi-functional flow cytometry and ELIspot assays for T cell responses as well as ELISAs, GIA assays and memory B cell ELIspot assays for humoral responses.



2. Assess IgG Fc effector functions in vivo by adoptive transfer of IgG from immunised volunteers into mice transgenic for different human Fc?Rs infected with a mouse malaria parasite chimeric for P. falciparum MSP119.



3. Attempt to correlate immunological readouts with efficacy in Phase IIa challenge studies.



4. Assess second generation vaccine strategies in humans using combinations of viral vector and protein-in-adjuvant vaccines.



5. Assess the effects of blood-stage malaria parasite exposure in UK volunteers on cellular and humoral immune responses.



6. Undertake baseline studies in African adults and children to measure i) cellular immune responses to blood-stage antigens, and ii) assess antibody Fc effector functions against MSP119 using the transgenic mouse model.</gtr:technicalSummary><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1104645</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Naval Medical Research Center Unit-6</gtr:collaboratingOrganisation><gtr:country>Peru, Republic of</gtr:country><gtr:department>Parasitology Department</gtr:department><gtr:description>US Navy NAMRU6</gtr:description><gtr:id>B2A2F271-AC0B-4A41-B5D4-4C8E3C6805C6</gtr:id><gtr:impact>Publication submitted.</gtr:impact><gtr:outcomeId>hMoRv2bQCVv-1</gtr:outcomeId><gtr:partnerContribution>Access to equipment and facilities.</gtr:partnerContribution><gtr:piContribution>Sharing of reagents. Training of staff in Peru.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ExpreS2ion Biotechnologies</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>ExpreS2ion Bio</gtr:description><gtr:id>468E2801-CF66-4179-91E0-E5B06E1FCB7E</gtr:id><gtr:impact>MRC DPFS grant awarded.
European Vaccine Initiative grant awarded.
PATH Malaria Vaccine Initiative grant awarded</gtr:impact><gtr:outcomeId>SBxLpZawsv4-1</gtr:outcomeId><gtr:partnerContribution>Access to research reagents.
Grant collaborator.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PATH</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>PATH Malaria Vaccine Initiative</gtr:department><gtr:description>PATH</gtr:description><gtr:id>6C4DEE90-4AAB-42E2-85C4-B456EF646909</gtr:id><gtr:impact>Publications and funding</gtr:impact><gtr:outcomeId>54539701c67c47.71092041-1</gtr:outcomeId><gtr:partnerContribution>Malaria vaccine development partnership</gtr:partnerContribution><gtr:piContribution>Malaria vaccine development partnership</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Centre for Genetic Engineering and Biotechnology</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>ICGEB</gtr:description><gtr:id>DF6373AC-463B-4695-A5B4-CBD76101C4E8</gtr:id><gtr:impact>Secured grant funding.
Publication.
PMID: 21813775</gtr:impact><gtr:outcomeId>Ko5Wob3E1Z6-1</gtr:outcomeId><gtr:partnerContribution>Sharing of research materials. MRC DCS grant collaborator.</gtr:partnerContribution><gtr:piContribution>Sharing of research materials and grant collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>GSK Biologicals SA</gtr:department><gtr:description>GSK Biopharm</gtr:description><gtr:id>EFB04AAC-35A4-4C7C-8A5D-81A43DB377CF</gtr:id><gtr:impact>No outcomes as yet</gtr:impact><gtr:outcomeId>56c1ec175f3a33.00064494-1</gtr:outcomeId><gtr:partnerContribution>Industrial partnership</gtr:partnerContribution><gtr:piContribution>Vaccine testing collaboration</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pfizer Rare Diseases</gtr:description><gtr:id>7433D530-51E6-4FE5-86B7-EC3478760170</gtr:id><gtr:impact>Grant funding</gtr:impact><gtr:outcomeId>56c1ef5e3a0941.38827533-1</gtr:outcomeId><gtr:partnerContribution>Industrial partnership</gtr:partnerContribution><gtr:piContribution>mAb and protein production</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Malaria GIA Reference Center - PATH MVI</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GIA Reference Centre, NIH</gtr:description><gtr:id>0364ACAE-6B7B-4151-9963-29F3507C29D7</gtr:id><gtr:impact>Publications.
PMID: 20713623
PMID: 21698193
PMID: 21799809
PMID: 21862998
PMID: 22186897
PMID: 22363582
PMID: 22984589
PMID: 23089736
PMID: 23144611
PMID: 23872520

Joint PhD student.</gtr:impact><gtr:outcomeId>UXWgj7XYbDC-1</gtr:outcomeId><gtr:partnerContribution>Significant experimental input.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>NIMR</gtr:description><gtr:id>691E50E8-6F3D-4007-9FB7-AC5EFB99C1A5</gtr:id><gtr:impact>Publications.
PMID: 20713623
PMID: 22504652
PMID: 21781305
PMID: 21698193</gtr:impact><gtr:outcomeId>stTUYSSpuaA-1</gtr:outcomeId><gtr:partnerContribution>Sharing of research reagents.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Burnet Institute</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Burnett Institute Australia</gtr:description><gtr:id>953C9E12-536E-4C21-8152-43BE841C8E51</gtr:id><gtr:impact>New scientific collaboration/reagents</gtr:impact><gtr:outcomeId>54638103008e64.47265906-1</gtr:outcomeId><gtr:partnerContribution>New scientific collaboration/reagents</gtr:partnerContribution><gtr:piContribution>New scientific collaboration/reagents</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Okairos/GSK</gtr:description><gtr:id>849752B2-C4EC-465D-ABDE-F6A37C7AF298</gtr:id><gtr:impact>Grants secured - EU FP7 MultiMalVax.
Publications.
PMID: 22363582
PMID: 21862998
PMID: 21098232
PMID: 20713623
PMID: 23089736
PMID: 21698193
PMID: 23293353</gtr:impact><gtr:outcomeId>RtAAzPcSmeK-1</gtr:outcomeId><gtr:partnerContribution>Access to expertise and reagents.
Vaccine manufacture.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Cork</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>Immunology</gtr:department><gtr:description>UCC</gtr:description><gtr:id>76F8E65E-BA47-4628-8B26-6AFDDC39F3EA</gtr:id><gtr:impact>Grant secured.
Publication.
PMID: 22245683</gtr:impact><gtr:outcomeId>mYWCdGU1N1m-1</gtr:outcomeId><gtr:partnerContribution>Sharing of research reagents.
Grant collaborator.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.
Training staff.
Grant collaborator.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>University of Bordeaux</gtr:description><gtr:id>AEB6D030-E9EC-4E48-9885-5A3AD9D1DC72</gtr:id><gtr:impact>New scientific collaboration/reagents</gtr:impact><gtr:outcomeId>54638000ac2104.68957274-1</gtr:outcomeId><gtr:partnerContribution>New scientific collaboration/reagents</gtr:partnerContribution><gtr:piContribution>New scientific collaboration/reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sanger Institute</gtr:description><gtr:id>D0D73A5F-FDBC-408A-96AD-9CA0EF3F70AE</gtr:id><gtr:impact>Publications.
PMID: 22186897
PMID: 23144611</gtr:impact><gtr:outcomeId>h8GQTDSpQPo-1</gtr:outcomeId><gtr:partnerContribution>Sharing of research reagents. 
Grant application collaborators.</gtr:partnerContribution><gtr:piContribution>Sharing of research reagents.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of the United States of America</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>United States Armed Forces</gtr:department><gtr:description>WRAIR</gtr:description><gtr:id>832BDE65-D052-4F9C-B48A-523430B27DE3</gtr:id><gtr:impact>New scientific collaboration/reagents</gtr:impact><gtr:outcomeId>5463819d8784b8.52432267-1</gtr:outcomeId><gtr:partnerContribution>New scientific collaboration/reagents</gtr:partnerContribution><gtr:piContribution>New scientific collaboration/reagents</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool School of Tropical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Parasite Immunology Liverpool</gtr:department><gtr:description>Antibody Fc Receptors</gtr:description><gtr:id>EAE70710-195C-4196-99A8-88C31636DCDC</gtr:id><gtr:impact>Publications.
PMID: 22984589
PMID: 21781305
PMID: 24163420
PMID: 23609325</gtr:impact><gtr:outcomeId>QRc8pbBZSo6-1</gtr:outcomeId><gtr:partnerContribution>Sharing of research materials</gtr:partnerContribution><gtr:piContribution>Sharing of materials. Contributions to publications.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>University of Oslo, Norway</gtr:description><gtr:id>DD617F87-2337-4B55-9AC1-1E0B1C6ABBC9</gtr:id><gtr:impact>Funding secured from GlobVac</gtr:impact><gtr:outcomeId>56c1f16c17be12.68054858-1</gtr:outcomeId><gtr:partnerContribution>Academic collaboration</gtr:partnerContribution><gtr:piContribution>Vaccine development collaboration for malaria</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:department>KEMRI-Wellcome Trust Research Programme</gtr:department><gtr:description>KEMRI Kilifi</gtr:description><gtr:id>87797085-2A63-41A5-BC5E-3EBC61EE4948</gtr:id><gtr:impact>Publications.
PMID: 22186897
PMID: 23144611</gtr:impact><gtr:outcomeId>Ko6awQLRr4N-1</gtr:outcomeId><gtr:partnerContribution>Sharing of research materials.</gtr:partnerContribution><gtr:piContribution>Sharing of materials. Contributions to publications.
Joint PhD student.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Visit, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CD3AE8BE-455B-4CEE-B642-D5586644B702</gtr:id><gtr:impact>Talk on Malaria, Ebola and Vaccines to 130 Year 6 pupils followed by questions afterwards.</gtr:impact><gtr:outcomeId>56b212a8b8ca50.87242152</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit. Nottingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D47A9C5-C579-4C12-85FF-342E033FBD07</gtr:id><gtr:impact>50 pupils attended a careers talk, which sparked questions and discussion afterwards

School asked for lab / university visit for sixth form pupils and university application guidance</gtr:impact><gtr:outcomeId>UXujuhRy1Zv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Online Interview</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2C626E7-0561-4BE2-A827-7A6B97BA4F66</gtr:id><gtr:impact>Online interview/podcast for the European Vaccine Initiative website

Online public engagement.</gtr:impact><gtr:outcomeId>p6kqsJMPt53</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>80,000 hours public talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>98865CF7-388A-4617-8879-4AF097FD0A72</gtr:id><gtr:impact>Lively discussion with public audience about vaccines and malaria

Increased public awareness about malaria and vaccines</gtr:impact><gtr:outcomeId>5463b243b95007.17367947</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>763088B7-412C-40F8-9185-28E80508A798</gtr:id><gtr:impact>Lively discussion with junior school children about vaccines, malaria and infectious diseases.

Positive feedback from teachers at the school</gtr:impact><gtr:outcomeId>5463b1bd5024c5.49708295</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Departmental Podcast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>282D0F06-35AB-4044-8274-7FC5CC14D71E</gtr:id><gtr:impact>Podcast about my reserach for Public access on the NDM website.

Public access on website.</gtr:impact><gtr:outcomeId>Qu1pjg32LiL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ndm.ox.ac.uk/simon-draper-progress-in-malaria-vaccine-research</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C80E432-E7BA-4684-A76C-84580B1AB778</gtr:id><gtr:impact>Radio interviews in the UK and Internation due to Press Release surrounding RH5 vaccine data publication in Nature Communications journal.

Increased public profile for this vaccine project.</gtr:impact><gtr:outcomeId>ZFXpNTA7kd6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Website Interview</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4EA2BA8E-9597-41F0-9FDB-8C6242F613DB</gtr:id><gtr:impact>Interview of the University of Oxford, Nuffield Department of Medicine website for WHO World Immunization Day</gtr:impact><gtr:outcomeId>56c1e5a2086e13.11398551</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ndm.ox.ac.uk/making-vaccines-more-effective</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trinity College Science Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3A16B7B-75BF-4FA2-89AB-D58BA5BCE0FE</gtr:id><gtr:impact>Talk on malaria and ebola vaccines to Trinity College Scientific Society</gtr:impact><gtr:outcomeId>56b45af34a2ea1.05287192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Oxford Public Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1A1054B3-D878-4EC4-B937-FAB5F0B69029</gtr:id><gtr:impact>Talk to about 50 members of the public at &amp;quot;Science Oxford&amp;quot; - a local organisation seeking to engage the public about science

Public engagement about malaria and vaccines.</gtr:impact><gtr:outcomeId>kJ75qwQC6WR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1901424</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Research Fellowship</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>106917/Z/15/Z</gtr:fundingRef><gtr:id>19ADC781-2ED1-4BFC-B67A-B7EEC615860B</gtr:id><gtr:outcomeId>56b335e4b65f12.67653352</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>483381</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Rare Diseases</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Pfizer Inc</gtr:fundingOrg><gtr:id>D8871D28-B9DD-4DCD-9890-BEDD14359F08</gtr:id><gtr:outcomeId>56b334d6205d71.66621188</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lister Institute Research Prize 2013</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Lister Institute of Preventive Medicine</gtr:fundingOrg><gtr:id>DB51F8A9-954E-48CF-A556-D570873DB612</gtr:id><gtr:outcomeId>ZMkmq7cDcqg</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1102333</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>PATH Malaria Vaccine Initiative</gtr:department><gtr:description>Clinical Trial for VAC054</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>PATH</gtr:fundingOrg><gtr:id>DC437587-20F5-4773-BBB3-BBAFA2336668</gtr:id><gtr:outcomeId>5453a89f2a9238.07489437</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>398884</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>GSK Biologicals SA</gtr:department><gtr:description>R&amp;amp;D Innovation Fund 2014</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>28B2F29A-0D3F-48B0-9CFE-3E92E9BE58B6</gtr:id><gtr:outcomeId>56b33130dc6375.07203534</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2964000</gtr:amountPounds><gtr:country>Norway, Kingdom of</gtr:country><gtr:currCode>NOK</gtr:currCode><gtr:currCountryCode>Norway</gtr:currCountryCode><gtr:currLang>no_NO</gtr:currLang><gtr:description>Research Council of Norway</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Research Council of Norway</gtr:fundingOrg><gtr:fundingRef>234431/H10</gtr:fundingRef><gtr:id>9248024E-5739-44FE-935E-2BCD6B6603E5</gtr:id><gtr:outcomeId>56b332fd5274f3.98676602</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96565</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>iCASE Studentship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N01796X/1</gtr:fundingRef><gtr:id>D478E88F-2DBA-4590-B558-5F666CCA4490</gtr:id><gtr:outcomeId>56b33b1790de19.30674362</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Grand Challenge Explorations</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>35C28CC2-624D-4517-96F2-EB1FF6130D32</gtr:id><gtr:outcomeId>pF5jHWJoAo4</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>LSTM MRC CiC</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A99C7362-DA54-449A-9F10-585D7278B804</gtr:id><gtr:outcomeId>5453aa2fd73845.77806536</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1274897</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K025554/1</gtr:fundingRef><gtr:id>FA7808AF-8109-42A3-B2BA-FE1103B79CD4</gtr:id><gtr:outcomeId>AdLBCCPUm9Z</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>79000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University Oxford Challenge Seed Fund</gtr:description><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>486F0694-307E-4264-A364-583C1B162C7C</gtr:id><gtr:outcomeId>EEtmT2BQUUg0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>University of Oxford MRC CiC</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6C52277A-D400-48B1-B2F8-49CFB4660886</gtr:id><gtr:outcomeId>5453aa8fcc0253.30280734</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EVIMalaR (FP7 Network of Excellence)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>541967D9-3036-4274-9ABB-A7288BCCE187</gtr:id><gtr:outcomeId>DX2KcP1rYEw0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>FP7 - MultiMalVax</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>323BBAC1-62E9-4982-B9DE-9D40AD38062F</gtr:id><gtr:outcomeId>rw29hrWCkn2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>77000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPhil Fellowship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>092873/Z/10/A</gtr:fundingRef><gtr:id>B29DF9BF-FB3F-43B2-A27A-6EFBFA5018A0</gtr:id><gtr:outcomeId>KzHMj1jo8vF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newton Phd Partnership Fund</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>82596CE8-2A00-43DB-80D6-DD779AAEE441</gtr:id><gtr:outcomeId>56b33a602b0734.98284354</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University Challenge Seed Fund</gtr:description><gtr:fundingOrg>ISIS</gtr:fundingOrg><gtr:id>063410C2-4614-402A-B30B-4AD12AEFE9F6</gtr:id><gtr:outcomeId>56b3308e76f761.07698067</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>109400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC iCASE PhD Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K017632/1</gtr:fundingRef><gtr:id>D9A244A4-668D-4B34-82BF-7582E05F6FF7</gtr:id><gtr:outcomeId>DRdLX2LdGWf</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>895435</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1100086</gtr:fundingRef><gtr:id>8C96C32B-718B-43F9-9CD0-B5B596D61F57</gtr:id><gtr:outcomeId>YXqP5v73sZk0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Vaccines based on RH5 structure</gtr:description><gtr:grantRef>G1000527</gtr:grantRef><gtr:id>32D35C81-DEEA-4FD7-818E-708EE6DB247B</gtr:id><gtr:impact>New vaccines in development</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54539f307d66a9.52432594</gtr:outcomeId><gtr:patentId>GB1413530.5</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>RH5 discontinuous fragments</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Immunogenic compositions of viral vaccines and adjuvants</gtr:description><gtr:grantRef>G1000527</gtr:grantRef><gtr:id>7B6EDBCE-9645-4ABC-A1D7-31F3AA35AC53</gtr:id><gtr:impact>Publication.
PMID: 20937436</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>Js3L5GghCbL</gtr:outcomeId><gtr:patentId>GB1016471.3</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Adjuvant Mixing</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Vaccines based on the malaria antigen RH5</gtr:description><gtr:grantRef>G1000527</gtr:grantRef><gtr:id>39FF7770-0CD2-4954-8837-E89D6CB1E8D3</gtr:id><gtr:impact>Publications
PMID: 23144611
PMID: 22186897</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>FxKR2H7zCVN</gtr:outcomeId><gtr:patentId>GB1103293.5</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>RH5 patent</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sanofi Pasteur Malaria Advisory Board Meeting</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>33431599-2214-4E16-8B37-225F4EF39644</gtr:id><gtr:outcomeId>Zf8bRnkopMN</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EVI European Vaccine Workshop</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>AFE731B0-FC3F-4049-9D41-6726BDB82858</gtr:id><gtr:outcomeId>56e0304f19ecf2.75089531</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26431986</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Prime-Boost Vaccine Meeting</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6C9189B4-CEF8-4798-9256-71BEC8DFDF35</gtr:id><gtr:outcomeId>FFgzx2Yju8f</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>African Training Symposium for Researchers - South Africa</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>3FA48E72-0100-4A6C-886E-E043FB7AFBEB</gtr:id><gtr:outcomeId>druWbka2e4j</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Jenner African Vaccinology Course</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:id>5C418BB3-E08B-4323-B4E1-471F64A96DEC</gtr:id><gtr:outcomeId>54539afae85530.96360273</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Jenner Oxford Vaccinology Course</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A59E1F3-9956-4673-8CC0-AD0568F56495</gtr:id><gtr:outcomeId>54539b6227d1b5.03873218</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>African Training Symposium for Researchers - Uganda</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>97F0C59E-844C-4105-ACF4-893B7A239BD2</gtr:id><gtr:outcomeId>U9PaHTPghjW</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AIDS Vaccine Research Subcommittee HIV Vaccine Advisory Meeting</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>5F3B584B-7E9C-4FCE-9EC9-35FB9FE7DB26</gtr:id><gtr:outcomeId>BGtB7rnsUfw</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Viral vectored vaccine against blood-stage Plasmodium falciparum - entered Phase Ia clinical trial in August 2014.</gtr:description><gtr:id>E81FB4F9-B5BD-4AE0-B33D-50FD7CCB6CED</gtr:id><gtr:impact>Publications and clinical trial funding</gtr:impact><gtr:outcomeId>dVqc9eHWCxb</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>P. falciparum viral vectored RH5 vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02181088?term=vac057&amp;rank=1</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mouse mAbs against the malaria antigen RH5</gtr:description><gtr:id>AF2B1855-3A08-4189-A44D-62F34C01070C</gtr:id><gtr:impact>Published</gtr:impact><gtr:outcomeId>gDdPXLgyeCd</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RH5 mouse mAbs</gtr:title><gtr:type>Antibody</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/24293631</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Structure of RH5 malaria protein for design of new vaccines and small molecule inhibitors</gtr:description><gtr:id>FA1B70C0-3B27-4851-9079-358C14A7AB1F</gtr:id><gtr:impact>Published</gtr:impact><gtr:outcomeId>5463b118c838e2.79603908</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RH5 structure</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/25132548</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A41158B5-321A-4982-9B77-D02364D08188</gtr:id><gtr:title>Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dbac0664cc171b38fab6d7e3d675e7a"><gtr:id>9dbac0664cc171b38fab6d7e3d675e7a</gtr:id><gtr:otherNames>Alharbi NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56c1e8b5931009.77847625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DBA6DEC-E737-42C5-9325-268549C6B723</gtr:id><gtr:title>Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6cedf1a9a74abf5931c4e490345c7f1"><gtr:id>b6cedf1a9a74abf5931c4e490345c7f1</gtr:id><gtr:otherNames>Wright KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>545393448a1b73.13202690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAF5A95D-E603-43FF-BF5D-B183524FB7AD</gtr:id><gtr:title>Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>ZvZ2qjnTPds</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34BC2647-F1C7-4AB3-A0E6-DA4ABA33A6A5</gtr:id><gtr:title>Immunisation against a serine protease inhibitor reduces intensity of Plasmodium berghei infection in mosquitoes.</gtr:title><gtr:parentPublicationTitle>International journal for parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60f32e856c91f8719ed1862e0d189adf"><gtr:id>60f32e856c91f8719ed1862e0d189adf</gtr:id><gtr:otherNames>Williams AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0020-7519</gtr:issn><gtr:outcomeId>pm_13035_25_23872520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EED9BE12-93AF-44EA-937E-CDCDB466A7E2</gtr:id><gtr:title>Recent developments in malaria vaccinology.</gtr:title><gtr:parentPublicationTitle>Advances in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d8aa753862332ce779a29fa326f5fc2"><gtr:id>9d8aa753862332ce779a29fa326f5fc2</gtr:id><gtr:otherNames>Halbroth BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0065-308X</gtr:issn><gtr:outcomeId>5675e32c8e000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C1C25BB-98E8-4E1F-9371-7392DAC1A91C</gtr:id><gtr:title>Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>pm_13035_25_23778312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F234BC4-0393-4AA6-8C78-F294AB8C75F1</gtr:id><gtr:title>Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13035_25_22363582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02FF61FB-25AB-49D8-A842-FE2834936E78</gtr:id><gtr:title>Role of Activins in Hepcidin Regulation during Malaria.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f74b171beed8655598b3801c6e65ac4"><gtr:id>8f74b171beed8655598b3801c6e65ac4</gtr:id><gtr:otherNames>Spottiswoode N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>5aa95ea85f1983.43491253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B7857CE-E186-4ADF-B5B3-DF3D55A22BD0</gtr:id><gtr:title>Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55e9c812cfbba94f1e7e00b693cdb8e1"><gtr:id>55e9c812cfbba94f1e7e00b693cdb8e1</gtr:id><gtr:otherNames>Wang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>585d6938c2b208.85315619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A629866D-3255-4EDE-8A9B-F58C5E2956EA</gtr:id><gtr:title>Toward the development of effective transmission-blocking vaccines for malaria.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3a78a66fa9e0fffa8685dd6c4781c13"><gtr:id>b3a78a66fa9e0fffa8685dd6c4781c13</gtr:id><gtr:otherNames>Nikolaeva D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>doi_55faa2aa204e09d9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81B42CA3-AAA3-447F-B775-590C934DE8D1</gtr:id><gtr:title>Controlled human blood stage malaria infection: current status and potential applications.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5706f9c76e406abe3c614f09d311abc1"><gtr:id>5706f9c76e406abe3c614f09d311abc1</gtr:id><gtr:otherNames>Duncan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>pm_13035_25_22492136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC3270C2-75D8-40E7-9A0D-C49FD7D329D5</gtr:id><gtr:title>ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_13035_25_23089736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68D14282-D3B2-4E7F-AE28-BAD7D4A022FF</gtr:id><gtr:title>Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f8fba304c35dd62dbda644b9b48af2"><gtr:id>b4f8fba304c35dd62dbda644b9b48af2</gtr:id><gtr:otherNames>Kapulu MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675e6423cb87</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B52D302-CB34-45A3-9164-E49727A9255B</gtr:id><gtr:title>The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13035_25_22186897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6618E5DD-C1A6-43A9-97F4-D76706CB1C5D</gtr:id><gtr:title>A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2630be4a1e7e453bf90f3caab49eb70b"><gtr:id>2630be4a1e7e453bf90f3caab49eb70b</gtr:id><gtr:otherNames>Ewer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56c1e9ea845b20.29950559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B50DDC68-9482-426E-BE22-FDA3C5245E5C</gtr:id><gtr:title>The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42a04bc2b2520d2067cacef47b23c82b"><gtr:id>42a04bc2b2520d2067cacef47b23c82b</gtr:id><gtr:otherNames>de Cassan SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>fKmNfJhQLtQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>908F9FF4-369D-42E2-9799-47AA6225393A</gtr:id><gtr:title>Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b171ee3c5bedb32926231c89f7e054"><gtr:id>76b171ee3c5bedb32926231c89f7e054</gtr:id><gtr:otherNames>Biswas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13035_25_22504652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE6810F1-9050-4FAA-9044-03625BFEC8A6</gtr:id><gtr:title>Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.</gtr:title><gtr:parentPublicationTitle>International journal for parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40adf277cdebdaa1cceb57dd629a1437"><gtr:id>40adf277cdebdaa1cceb57dd629a1437</gtr:id><gtr:otherNames>Jin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0020-7519</gtr:issn><gtr:outcomeId>58999845869ed5.38360898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17D366E6-8E36-4230-9D40-8ABEDB033B00</gtr:id><gtr:title>Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b171ee3c5bedb32926231c89f7e054"><gtr:id>76b171ee3c5bedb32926231c89f7e054</gtr:id><gtr:otherNames>Biswas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>EJ6ZNYU3iAd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E07751E-0E36-4F64-ABE8-7F4B2662A746</gtr:id><gtr:title>A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>doi_55f9859856c4520d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7AC9EA-C0E0-4478-B24D-AAD5D8F2CCB3</gtr:id><gtr:title>Workshop report: Malaria vaccine development in Europe--preparing for the future.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9179dca6a25601443fc585224422e50f"><gtr:id>9179dca6a25601443fc585224422e50f</gtr:id><gtr:otherNames>Viebig NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56c1e9578babe4.68622781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76C62243-60E5-43F4-98E8-15526DE71132</gtr:id><gtr:title>Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dbac0664cc171b38fab6d7e3d675e7a"><gtr:id>9dbac0664cc171b38fab6d7e3d675e7a</gtr:id><gtr:otherNames>Alharbi NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e5325eefe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D07335-6A24-4C5A-9E80-4FE0CF8DCAF1</gtr:id><gtr:title>Recent advances in recombinant protein-based malaria vaccines.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56c1e911e18bc5.38306517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97054C94-301B-4AC9-9685-59C4580A6C1B</gtr:id><gtr:title>Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60f32e856c91f8719ed1862e0d189adf"><gtr:id>60f32e856c91f8719ed1862e0d189adf</gtr:id><gtr:otherNames>Williams AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13035_25_23144611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E114051-7854-423F-A5E0-3FAA5A449B49</gtr:id><gtr:title>Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a65259c0b4f15be65eecfe8ce12e772"><gtr:id>7a65259c0b4f15be65eecfe8ce12e772</gtr:id><gtr:otherNames>Hodgson SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>545393f0cf5411.84322439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>637A1C52-D8CA-4CD0-B8C3-BCBBB34D0353</gtr:id><gtr:title>Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2787dfca57d8c2fdc2e07cd71617963"><gtr:id>a2787dfca57d8c2fdc2e07cd71617963</gtr:id><gtr:otherNames>Ewer KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13035_25_24284865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA7930E8-CD7B-4390-8BB8-9FBEA6798F32</gtr:id><gtr:title>T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13035_25_22984589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E48BB40-4348-4DBA-913F-09E4A72C403A</gtr:id><gtr:title>Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94597ce1c526a37472084c4530917644"><gtr:id>94597ce1c526a37472084c4530917644</gtr:id><gtr:otherNames>Carey JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>545393f1006ba2.22920910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>449792EE-C9E0-4783-9347-AA6B0575415F</gtr:id><gtr:title>Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd75dbe105014309cbdded985198a393"><gtr:id>bd75dbe105014309cbdded985198a393</gtr:id><gtr:otherNames>Li Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56c1e86d48aed5.01109688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70B0B31E-D195-4C12-A04D-E5F3CA4FDCE1</gtr:id><gtr:title>Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>ZfJgJ5hhBPy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB7FF987-BE43-4EA3-A22B-D69DEC98BF70</gtr:id><gtr:title>Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a65259c0b4f15be65eecfe8ce12e772"><gtr:id>7a65259c0b4f15be65eecfe8ce12e772</gtr:id><gtr:otherNames>Hodgson SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>doi_55faa2aa204502be</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>888B7674-3724-4837-B620-5BCFED783411</gtr:id><gtr:title>The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19).</gtr:title><gtr:parentPublicationTitle>BMC biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1472-6750</gtr:issn><gtr:outcomeId>CAreeScrub5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43145F02-F37D-4946-8EDE-7F21F418C13A</gtr:id><gtr:title>Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42a04bc2b2520d2067cacef47b23c82b"><gtr:id>42a04bc2b2520d2067cacef47b23c82b</gtr:id><gtr:otherNames>de Cassan SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5675e970dfa10</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C14E7B6-6FAC-42D3-819B-1917A4AC7CFA</gtr:id><gtr:title>Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>KsW5VRMDJyR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D4C668F-A442-4ABB-BB96-F466941AD3FE</gtr:id><gtr:title>Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba120ad0efef8b4c8420f4874b56f752"><gtr:id>ba120ad0efef8b4c8420f4874b56f752</gtr:id><gtr:otherNames>Llewellyn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675eb936fdfc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55BEB4FF-D273-4247-AA88-D03E305B7461</gtr:id><gtr:title>Progress with viral vectored malaria vaccines: A multi-stage approach involving &amp;quot;unnatural immunity&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2787dfca57d8c2fdc2e07cd71617963"><gtr:id>a2787dfca57d8c2fdc2e07cd71617963</gtr:id><gtr:otherNames>Ewer KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56c1e8e8a499d5.59976143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE7A6B65-4A6F-4B31-B01D-62AD58581868</gtr:id><gtr:title>Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>izeVwXTQe1G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2A05978-862E-4695-A7DD-BFEEE379D010</gtr:id><gtr:title>Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a65259c0b4f15be65eecfe8ce12e772"><gtr:id>7a65259c0b4f15be65eecfe8ce12e772</gtr:id><gtr:otherNames>Hodgson SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>doi_55faa2aa2057ea21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E9F102D-FFE2-4D38-9D02-FDE19E191997</gtr:id><gtr:title>Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b171ee3c5bedb32926231c89f7e054"><gtr:id>76b171ee3c5bedb32926231c89f7e054</gtr:id><gtr:otherNames>Biswas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54539261267b05.40716847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7562CC58-E3D9-43D6-A1A4-449A65EA3A50</gtr:id><gtr:title>Accelerating vaccine development and deployment: report of a Royal Society satellite meeting.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6cbaeb19ba46809476c72399600d38d"><gtr:id>d6cbaeb19ba46809476c72399600d38d</gtr:id><gtr:otherNames>Bregu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>goKizdrLDTv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AB056DB-7631-4FA2-AF28-FE5BBD6317A1</gtr:id><gtr:title>Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42a04bc2b2520d2067cacef47b23c82b"><gtr:id>42a04bc2b2520d2067cacef47b23c82b</gtr:id><gtr:otherNames>de Cassan SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>545393f1609e24.75555591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FDBDCA9-02A3-411F-8561-6E184A257B76</gtr:id><gtr:title>Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e431dee7e091b64744115afa9fea7ab"><gtr:id>1e431dee7e091b64744115afa9fea7ab</gtr:id><gtr:otherNames>Payne RO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>585d693592df72.63398671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D228828-F370-40C9-B9AE-3A087C770DA8</gtr:id><gtr:title>Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13035_25_24293631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B05ADC2-A3AA-494D-ADDF-14B473A89D0A</gtr:id><gtr:title>Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b46faaea29d65e5176dd6a77eddc991"><gtr:id>2b46faaea29d65e5176dd6a77eddc991</gtr:id><gtr:otherNames>Elias SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>54614f82c74758.37244983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70FCC118-D339-4987-9C30-B9E5E75839A4</gtr:id><gtr:title>Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b46faaea29d65e5176dd6a77eddc991"><gtr:id>2b46faaea29d65e5176dd6a77eddc991</gtr:id><gtr:otherNames>Elias SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>54539434cb2e87.75947227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76C3A8A5-D86E-44BA-8352-C38154B71820</gtr:id><gtr:title>Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a033b63cce50354d377a5446bae3bd"><gtr:id>b9a033b63cce50354d377a5446bae3bd</gtr:id><gtr:otherNames>Murungi LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>56c1e81171ddb6.12286589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C12421A6-1043-4065-B7C3-27DF6AFA38F4</gtr:id><gtr:title>Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>heLVXvWb3kc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>382740DE-9C5E-4AE3-BFFF-5FA0A7927ED5</gtr:id><gtr:title>Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba120ad0efef8b4c8420f4874b56f752"><gtr:id>ba120ad0efef8b4c8420f4874b56f752</gtr:id><gtr:otherNames>Llewellyn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_13035_25_24163420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>364936FB-D965-420F-B8D2-0427BE0DE1E2</gtr:id><gtr:title>Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5706f9c76e406abe3c614f09d311abc1"><gtr:id>5706f9c76e406abe3c614f09d311abc1</gtr:id><gtr:otherNames>Duncan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>A9vtapipooi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D116340-D040-4DE4-8126-FA89E5F74811</gtr:id><gtr:title>Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8656f544d10895865b3875383eed85ab"><gtr:id>8656f544d10895865b3875383eed85ab</gtr:id><gtr:otherNames>Spencer AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13035_25_22470455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08F8A246-5304-449A-8B48-7576A5DFC24E</gtr:id><gtr:title>New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>dF7tnn2MZJ8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C991595-25AC-443E-AD26-80A8B30700CB</gtr:id><gtr:title>Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a65259c0b4f15be65eecfe8ce12e772"><gtr:id>7a65259c0b4f15be65eecfe8ce12e772</gtr:id><gtr:otherNames>Hodgson SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>56c1e9b6da6269.87020341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DA465CD-00AD-4886-A860-B2664C1EE783</gtr:id><gtr:title>A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13035_25_22216279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CD8CD97-986E-4493-A9E4-A3363E9A87E5</gtr:id><gtr:title>Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_13035_25_23746455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E18B1DE7-CA8C-4EDF-8084-4180610D971F</gtr:id><gtr:title>Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>545393f1301b67.87380666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85AE016F-A14A-48F9-B622-1DB6D6491F95</gtr:id><gtr:title>Malaria Vaccines: Moving Forward After Encouraging First Steps.</gtr:title><gtr:parentPublicationTitle>Current tropical medicine reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7b8f49b70ded4e3263e884661956e78"><gtr:id>a7b8f49b70ded4e3263e884661956e78</gtr:id><gtr:otherNames>Tran TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c1e99106f174.56435093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4EA5382-E17C-4D7F-B6B7-2D439C830DD5</gtr:id><gtr:title>The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_13035_25_23609325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AAC5A07-20C5-4D54-867F-86B52D78CBF7</gtr:id><gtr:title>Coated microneedle arrays for transcutaneous delivery of live virus vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a361f04e0a6d395f48073d8b352e599"><gtr:id>8a361f04e0a6d395f48073d8b352e599</gtr:id><gtr:otherNames>Vrdoljak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>pm_13035_25_22245683</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000527</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>